Long-Term Efficacy and Safety of Zanubrutinib in Patients with Relapsed/Refractory (R/R) Marginal Zone Lymphoma (MZL): Final Analysis of the Magnolia (BGB-3111-214) Trial
Kim M. Linton,Judith Trotman,Pamela Mckay,Kirit Ardeshna,Sunil Iyengar,Alessandra Tedeschi,Bei Hu,Sophie Leitch,Jie Jin,Mingyuan Sun,Magdalena Sobieraj-Teague,Pier Luigi Zinzani,Peter Browett,Xiaoyan Ke,Craig A. Portell,Catherine Thieblemont,Fontanet Bijou,Patricia Walker,Eliza A. Hawkes,Shir-Jing Ho,Keshu Zhou,Zhiyu Liang,Jianfeng Xu,Chris Tankersley,Richard Delarue,Melannie Co,Stephen Opat
DOI: https://doi.org/10.1182/blood-2022-163371
2023-01-01
Transplantation and Cellular Therapy
Abstract:Introduction: ZANU (BGB-3111), a potent next-generation Bruton tyrosine kinase inhibitor, is approved in various countries for R/R MZL based on the MAGNOLIA study (NCT03846427) primary analysis. At a median follow-up of 28 months (mo), we present the MAGNOLIA study final analysis. Methods: Eligible adult patients (pts) received ZANU 160 mg twice daily until disease progression/unacceptable toxicity. Primary endpoint was overall response rate (ORR) by independent review committee (IRC) in accordance with Lugano 2014 classification. Secondary endpoints included ORR by investigator assessment, duration of response (DOR), progression-free survival (PFS), overall survival (OS), and safety. Efficacy was assessed by positron emission tomography (PET)-based Lugano criteria for pts with IRC-confirmed fluorodeoxyglucose (FDG)-avid disease at baseline; non-avid pts were assessed by computed tomography (CT)-based criteria. A sensitivity analysis using only CT-based criteria was also performed. Results: As of May 4, 2022, 68 pts were enrolled and treated (70 [range: 37–95] median years); 66 pts were efficacy-evaluable (median follow-up 28.0 mo [range: 1.6–32.9]; median treatment duration 24.2 mo [range: 0.9–32.0]). Pts had the following MZL subtypes: 38.2% extranodal (mucosa-associated lymphoid tissue), 38.2% nodal, 17.6% splenic, 5.9% unknown. Sixty-one (89.7%) pts had IRC-assessed FDG-avid disease. IRC-assessed ORR (complete response [CR] + partial response [PR]) was 68.2% (CR 25.8%; Table). ORR (CR rate) was 64.0% (40.0%) in extranodal, 76.0% (20.0%) in nodal, 66.7% (8.3%) in splenic, and 50.0% (25.0%) in unknown subtypes. Median DOR, PFS, and OS were not reached. At the 2-year landmark by IRC, >70.0% of pts were alive/progression-free. Sensitivity analysis using only CT-based criteria (n = 66) by IRC showed an ORR of 66.7% (CR 24.2%). Median DOR and median PFS were not reached. At study completion, 31 (45.6%) pts deriving benefit rolled over to a long-term extension study (NCT04170283); 24 (35.3%) discontinued due to disease progression (investigator assessed); 5 (7.4%) to adverse events (AEs), 2 (2.9%) required prohibited medications, and 1 (1.5%) withdrew consent. Most common treatment-emergent AEs in >20% of pts were bruising (23.5%) and diarrhea (22.1%). Neutropenia (8.8%) and COVID-19 pneumonia (5.9%) were the most common grade ≥3 AEs. Five (7.4%) pts died due to unrelated AEs (2 COVID-19 pneumonia, 1 acute myeloid leukemia [prior alkylating agent exposure], 1 myocardial infarction [preexisting coronary artery disease], 1 septic encephalopathy [pt in CR]). Hypertension occurred in 3 (4.4%) pts, atrial fibrillation and atrial flutter in 1 (1.5%) pt; none led to treatment withdrawal. Conclusions: With >2 years of median study follow-up, ZANU continues to demonstrate high response rates, durable disease control, and is well tolerated with no new safety signals observed. Encore Abstract - previously submitted to EHA 2023 The research was funded by: BeiGene Keywords: Indolent non-Hodgkin lymphoma, Molecular Targeted Therapies, Targeting the Tumor Microenvironment Conflicts of interests pertinent to the abstract. J. Trotman Research funding: BeiGene, Janssen, PCYC, Roche, Celgene BMS, Selectar A. Tedeschi Honoraria: Janssen, AbbVie, AstraZeneca, BeiGene Educational grants: Janssen, AbbVie, BeiGene, AstraZeneca B. Hu Consultant or advisory role: BeiGene, ADC Therapeautics, Morphosys Research funding: BeiGene, Roche, BMS/Celgene K. M. Linton Consultant or advisory role: Celgene, Gilead/Kite, BeiGene, Genmab, Roche Other remuneration: Speakers Bureau: Genmab P. McKay Honoraria: Roche; BeiGene; Recordati rare Disease; Gilead/KITE; Celgene/BMS; Takeda; AstraZeneca; AbbvVe; Epizyme; Incyte Educational grants: Takeda Other remuneration: Speakers Bureau: Janssen; Incyte; Roche; Kite J. Jin Educational grants: BeiGene P. L. Zinzani Consultant or advisory role: Secura Bio, Celltrion, Gilead, Janssen-Cilag, BMS, Servier, Sandoz, MSD, AstraZeneca, Takeda, Roche, Eusa Pharma, Kyowa Kirin, Novartis, ADC Therapeutics, Incyte, BeiGene Other remuneration: Speakers Bureau: Celltrion, Gilead, Janssen-Cilag, BMS, Servier, MSD, AstraZeneca, Takeda, Roche, Eusa Pharma, Kyowa Kirin, Novartis, Incyte, BeiGene P. Browett Consultant or advisory role: Eysa Pharma, Janssen Honoraria: AbbVie, Arrowhead, MSD Research funding: Roche, BeiGene C. Thieblemont Consultant or advisory role: Roche, AbbVie, Genmab, Kite/Gilead, Takeda, Novartis, Incyte, Celgene, BMS Research funding: Roche Educational grants: Novartis, Gilead, BMS E. Bachy Consultant or advisory role: Takeda, Roche, Gilead Honoraria: Roche, Gilead, Novartis Research funding: Amgen Educational grants: AbbVie, Incyte F. Cavallo Consultant or advisory role: Roche Honoraria: AstraZaneca Research funding: Roche Educational grants: Roche, BeiGene, Takeda, Amgen Other remuneration: Speakers Bureau: Servier S. Iyengar Consultant or advisory role: Takeda, Kite, BeiGene, Lilly Honoraria: Takeda, AbbVie Other remuneration: Speakers Bureau: Takeda, Janssen R. Marasca Consultant or advisory role: Janssen Honoraria: AbbVie, AstraZeneca, BeiGene Educational grants: AbbVie, BeiGene H. Mociková Consultant or advisory role: Takeda, Roche, AstraZeneca, Janssen, AbbvVe Educational grants: Janssen, Takeda D. Talaulikar Consultant or advisory role: EUSA, CSL, Amgen, Takeda, Antengene, MSL, BeiGene, Roche Stock ownership: Immutep Honoraria: EUSA, CSL, Amgen, Takeda, Antengene, MSL, BeiGene, Roche Research funding: Roche, Janssen Other remuneration: Speakers Bureau: BeiGene, Roche, MSL Z. Liang Employment or leadership position: BeiGene Ltd. Stock ownership: BeiGene Ltd. J. Xu Employment or leadership position: BeiGene Stock ownership: BeiGene C. Tankersley Employment or leadership position: BeiGene Ltd. Stock ownership: BeiGene Ltd. Educational grants: BeiGene Ltd. R. Delarue Employment or leadership position: BeiGene Stock ownership: BeiGene M. Co Employment or leadership position: BeiGene Ltd. Stock ownership: BeiGene Ltd. Educational grants: BeiGene Ltd. S. Opat Consultant or advisory role: AbbVie, Antengene, AstraZeneca, BeiGene, BMS, CSL Behring, Gilead, Merck, Novartis, Janssen, Roche, Takeda Honoraria: AbbVie, AstraZeneca, BeiGene, BMS, Gilead, Janssen, Merck, Novartis, Roche, Takeda Research funding: AbbVie, AstraZeneca, BeiGene, BMS, Gilead, Janssen, Merck, Novartis, Pharmacyclics, Roche, Takeda